Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

PhRMA Offers Consumers Online Resources on Biologics and Biosimilars

PhRMA jpgWashington, DC, March 27, 2016 ― Biological medicines often represent the cutting-edge of biomedical research and have revolutionized the treatment of a variety of medical illnesses and conditions that presently have no other treatments available.

A biosimilar product is exactly what its name implies — it is a biologic that is “similar” to another biologic drug already approved by the FDA.

To help increase awareness and understanding of the important scientific, regulatory and reimbursement policies for these medicines, the Pharmaceutical Research and Manufacturers of America (PhRMA) has launched a new section of our website today that provides educational resources on these topics.

Within the new website section, you can find the following information:

  • How biologics and biosimilars work;
  • What data protection measures are in place to promote research and development of these medicines; and,
  • How science-based regulatory policies protect patient safety and facilitate health care provider and patient choice.

Additionally, a number of downloadable fact sheets and infographics are available on more in-depth biologics and biosimilars topics.

As the regulatory environment surrounding these medicines continues to evolve, PhRMA will develop and offer additional resources on the page that provide key facts on these milestones.Biologics_icon.jpg

To access the new biologics and biosimilars web page, go to:  www.PhRMA.org/Biosimilars

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives.  Since 2000, PhRMA member companies have invested more than $600 billion in the search for new treatments and cures, including an estimated $51.2 billion in 2014 alone.